Robab B. K.
- Country
- Austria
- Department
- Abteilung für Lungen- und Atmungserkrankungen
Research Overview
- A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Admilparant in Participants with Progressive Pulmonary Fibrosis
- A Phase 2b Dose-Ranging Study of Oral KT-621 in Adults with Uncontrolled Moderate to Severe Eosinophilic Asthma
- Efficacy and Safety of Oral Dexpramipexole in Adolescents and Adults with Severe Eosinophilic Asthma: A Randomized, Double-Blind, Placebo-Controlled Study
Data & Insights
Has run more than one trial at 127 of 442 partner sites.
Specializations
Respiratory Medicine
The investigator specializes in severe eosinophilic asthma management, focusing on innovative therapeutic approaches for patients with severe and persistent symptoms.
- Bronchial inflammation control
- Asthma exacerbation management
- Novel therapeutic agents
Their work explores advanced treatment options for managing severe asthmatic conditions requiring specialized intervention.
Oncology - Lung Cancer
Primary research concentration is on non-small cell lung cancer and small cell lung cancer, with particular attention to advanced and metastatic disease states.
- NSCLC treatment strategies
- Extensive stage SCLC therapy
- Neoadjuvant treatment approaches
The investigator addresses various stages of lung cancer, from resectable to metastatic disease presentations.
Precision Oncology
Expertise extends to targeted therapies for specific genetic mutations, particularly focusing on KRAS G12C-mutated lung cancer and immunotherapy applications.
- Targeted molecular therapy
- Immunotherapy combinations
- Personalized treatment approaches
Their research encompasses both monotherapy and combination treatment strategies in advanced lung cancer settings.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.